Love this stretch with the review of the heavy-hitter HF studies (also dating myself to note they bring me back to my trainee days).
Sadly, in Canada, metoprolol succinate (ie. Toprol XL) was never approved /marketed, so we only have the tartrate formulation.
And due to the alpha-1 blocker effects with carvedilol (which in my experience account for a non-negligible amount of hypotensive side effects), I’m left with mostly using bisoprolol. I imagine this review might saunter to CIBIS 1 and 2 but would love to hear your appraisal of COMET (which makes me shy away from metoprolol tartrate although IIRC that trial had dosing issues that biased against metoprolol).
Love this stretch with the review of the heavy-hitter HF studies (also dating myself to note they bring me back to my trainee days).
Sadly, in Canada, metoprolol succinate (ie. Toprol XL) was never approved /marketed, so we only have the tartrate formulation.
And due to the alpha-1 blocker effects with carvedilol (which in my experience account for a non-negligible amount of hypotensive side effects), I’m left with mostly using bisoprolol. I imagine this review might saunter to CIBIS 1 and 2 but would love to hear your appraisal of COMET (which makes me shy away from metoprolol tartrate although IIRC that trial had dosing issues that biased against metoprolol).
CIBIS 2 and COMET will be reviewed soon!
A great result from a great trial